Stem definition | Drug id | CAS RN |
---|---|---|
retinol derivatives | 78 | 55079-83-9 |
Dose | Unit | Route |
---|---|---|
35 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.83 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 59 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 28, 1996 | FDA | STIEFEL LABS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 885.31 | 22.45 | 388 | 9003 | 92304 | 56190372 |
Skin haemorrhage | 237.10 | 22.45 | 78 | 9313 | 8335 | 56274341 |
Skin exfoliation | 185.40 | 22.45 | 100 | 9291 | 36800 | 56245876 |
Neurologic neglect syndrome | 157.58 | 22.45 | 42 | 9349 | 2156 | 56280520 |
Carotid artery thrombosis | 156.72 | 22.45 | 42 | 9349 | 2202 | 56280474 |
Respiratory tract congestion | 131.08 | 22.45 | 60 | 9331 | 15531 | 56267145 |
Personality disorder | 122.12 | 22.45 | 42 | 9349 | 5131 | 56277545 |
Sneezing | 118.75 | 22.45 | 56 | 9335 | 15504 | 56267172 |
Sinus congestion | 118.19 | 22.45 | 56 | 9335 | 15668 | 56267008 |
Sinus disorder | 103.53 | 22.45 | 56 | 9335 | 20678 | 56261998 |
Sensory loss | 103.15 | 22.45 | 43 | 9348 | 8892 | 56273784 |
Hemiplegia | 102.28 | 22.45 | 42 | 9349 | 8362 | 56274314 |
Affect lability | 97.97 | 22.45 | 43 | 9348 | 10082 | 56272594 |
Motor dysfunction | 97.50 | 22.45 | 42 | 9349 | 9415 | 56273261 |
Adjustment disorder | 92.27 | 22.45 | 28 | 9363 | 2295 | 56280381 |
Psoriatic arthropathy | 89.69 | 22.45 | 84 | 9307 | 73924 | 56208752 |
Coordination abnormal | 85.90 | 22.45 | 42 | 9349 | 12579 | 56270097 |
Rhinorrhoea | 85.47 | 22.45 | 73 | 9318 | 56964 | 56225712 |
Eating disorder | 73.88 | 22.45 | 42 | 9349 | 17063 | 56265613 |
Muscle spasticity | 70.42 | 22.45 | 43 | 9348 | 19917 | 56262759 |
Hemiparesis | 67.50 | 22.45 | 43 | 9348 | 21447 | 56261229 |
Cutaneous T-cell lymphoma | 60.78 | 22.45 | 18 | 9373 | 1357 | 56281319 |
Cystitis | 58.10 | 22.45 | 55 | 9336 | 48983 | 56233693 |
Erythrodermic psoriasis | 57.48 | 22.45 | 16 | 9375 | 966 | 56281710 |
Aphasia | 56.20 | 22.45 | 44 | 9347 | 30371 | 56252305 |
Skin plaque | 55.74 | 22.45 | 26 | 9365 | 7012 | 56275664 |
Influenza | 54.37 | 22.45 | 73 | 9318 | 95188 | 56187488 |
Infected dermal cyst | 53.98 | 22.45 | 13 | 9378 | 441 | 56282235 |
Pustular psoriasis | 53.19 | 22.45 | 22 | 9369 | 4456 | 56278220 |
Skin lesion | 52.63 | 22.45 | 41 | 9350 | 28094 | 56254582 |
Rhesus antigen positive | 51.06 | 22.45 | 10 | 9381 | 124 | 56282552 |
Rash pustular | 50.87 | 22.45 | 24 | 9367 | 6639 | 56276037 |
Oral lichen planus | 50.37 | 22.45 | 13 | 9378 | 587 | 56282089 |
Influenza like illness | 49.79 | 22.45 | 56 | 9335 | 60932 | 56221744 |
Erythema | 49.19 | 22.45 | 91 | 9300 | 155848 | 56126828 |
Pruritus | 47.74 | 22.45 | 138 | 9253 | 316485 | 55966191 |
Drug ineffective | 46.60 | 22.45 | 286 | 9105 | 918703 | 55363973 |
Dysarthria | 44.27 | 22.45 | 43 | 9348 | 39507 | 56243169 |
Dry skin | 43.22 | 22.45 | 46 | 9345 | 47063 | 56235613 |
Arterial occlusive disease | 42.89 | 22.45 | 20 | 9371 | 5390 | 56277286 |
Gangrene | 42.43 | 22.45 | 20 | 9371 | 5520 | 56277156 |
Squamous cell carcinoma | 40.63 | 22.45 | 22 | 9369 | 8126 | 56274550 |
Angina pectoris | 40.23 | 22.45 | 35 | 9356 | 27941 | 56254735 |
Guttate psoriasis | 40.22 | 22.45 | 10 | 9381 | 388 | 56282288 |
Dysphagia | 38.16 | 22.45 | 57 | 9334 | 81890 | 56200786 |
Weaning failure | 36.85 | 22.45 | 9 | 9382 | 324 | 56282352 |
Wrong technique in device usage process | 36.56 | 22.45 | 15 | 9376 | 2975 | 56279701 |
Lichen planus | 34.09 | 22.45 | 13 | 9378 | 2129 | 56280547 |
Blood immunoglobulin M decreased | 32.83 | 22.45 | 10 | 9381 | 829 | 56281847 |
Skin fissures | 32.17 | 22.45 | 20 | 9371 | 9553 | 56273123 |
Blood albumin increased | 32.06 | 22.45 | 10 | 9381 | 898 | 56281778 |
Burning sensation | 31.94 | 22.45 | 40 | 9351 | 48656 | 56234020 |
Pain of skin | 31.44 | 22.45 | 19 | 9372 | 8627 | 56274049 |
Oesophageal stenosis | 29.88 | 22.45 | 13 | 9378 | 2980 | 56279696 |
Immunoglobulins decreased | 29.85 | 22.45 | 10 | 9381 | 1127 | 56281549 |
Tongue ulceration | 29.13 | 22.45 | 13 | 9378 | 3166 | 56279510 |
Palmoplantar pustulosis | 28.90 | 22.45 | 8 | 9383 | 473 | 56282203 |
Type IIb hyperlipidaemia | 28.77 | 22.45 | 5 | 9386 | 30 | 56282646 |
Ichthyosis | 27.52 | 22.45 | 5 | 9386 | 40 | 56282636 |
Nasopharyngitis | 27.35 | 22.45 | 90 | 9301 | 220869 | 56061807 |
Inflammatory bowel disease | 27.02 | 22.45 | 13 | 9378 | 3755 | 56278921 |
Toxicity to various agents | 26.95 | 22.45 | 3 | 9388 | 224561 | 56058115 |
Increased bronchial secretion | 26.46 | 22.45 | 10 | 9381 | 1597 | 56281079 |
Oesophageal ulcer | 25.86 | 22.45 | 13 | 9378 | 4126 | 56278550 |
Injection site bruising | 25.83 | 22.45 | 32 | 9359 | 38489 | 56244187 |
Sunburn | 25.14 | 22.45 | 11 | 9380 | 2557 | 56280119 |
Arthritis | 25.07 | 22.45 | 53 | 9338 | 99799 | 56182877 |
Keratoacanthoma | 24.79 | 22.45 | 7 | 9384 | 445 | 56282231 |
Skin atrophy | 24.75 | 22.45 | 13 | 9378 | 4517 | 56278159 |
Swelling | 24.67 | 22.45 | 5 | 9386 | 239766 | 56042910 |
Tanning | 24.52 | 22.45 | 5 | 9386 | 77 | 56282599 |
Onychalgia | 24.42 | 22.45 | 8 | 9383 | 841 | 56281835 |
Face oedema | 24.36 | 22.45 | 22 | 9369 | 18430 | 56264246 |
Blood immunoglobulin G decreased | 23.48 | 22.45 | 10 | 9381 | 2176 | 56280500 |
Rebound psoriasis | 23.20 | 22.45 | 5 | 9386 | 102 | 56282574 |
Inappropriate schedule of product administration | 22.98 | 22.45 | 46 | 9345 | 83341 | 56199335 |
Mean cell haemoglobin increased | 22.58 | 22.45 | 10 | 9381 | 2390 | 56280286 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 766.47 | 23.33 | 305 | 6204 | 46414 | 31644421 |
Drug ineffective | 191.91 | 23.33 | 311 | 6198 | 395262 | 31295573 |
Vein rupture | 187.38 | 23.33 | 41 | 6468 | 725 | 31690110 |
Skin plaque | 172.87 | 23.33 | 54 | 6455 | 3961 | 31686874 |
Venous injury | 108.16 | 23.33 | 22 | 6487 | 268 | 31690567 |
Pityriasis rubra pilaris | 106.89 | 23.33 | 19 | 6490 | 104 | 31690731 |
Injection site haemorrhage | 100.25 | 23.33 | 45 | 6464 | 9040 | 31681795 |
Erythrodermic psoriasis | 89.56 | 23.33 | 23 | 6486 | 824 | 31690011 |
Injection site papule | 83.52 | 23.33 | 18 | 6491 | 295 | 31690540 |
Psoriatic arthropathy | 82.03 | 23.33 | 51 | 6458 | 19832 | 31671003 |
Cutaneous T-cell lymphoma | 77.94 | 23.33 | 23 | 6486 | 1388 | 31689447 |
Dermatitis exfoliative generalised | 77.78 | 23.33 | 28 | 6481 | 3171 | 31687664 |
Skin injury | 76.74 | 23.33 | 24 | 6485 | 1763 | 31689072 |
Injection site swelling | 74.73 | 23.33 | 38 | 6471 | 10049 | 31680786 |
Inappropriate schedule of product administration | 70.14 | 23.33 | 68 | 6441 | 50755 | 31640080 |
Pain of skin | 67.36 | 23.33 | 27 | 6482 | 4099 | 31686736 |
Therapeutic product effect incomplete | 67.03 | 23.33 | 62 | 6447 | 43634 | 31647201 |
Hepatic fibrosis | 62.03 | 23.33 | 25 | 6484 | 3849 | 31686986 |
Squamous cell carcinoma | 61.37 | 23.33 | 34 | 6475 | 10677 | 31680158 |
Pruritus | 59.27 | 23.33 | 98 | 6411 | 125069 | 31565766 |
Skin erosion | 55.68 | 23.33 | 19 | 6490 | 1837 | 31688998 |
Drug intolerance | 54.40 | 23.33 | 60 | 6449 | 51973 | 31638862 |
Granuloma annulare | 53.92 | 23.33 | 11 | 6498 | 136 | 31690699 |
Hepatic cirrhosis | 51.82 | 23.33 | 35 | 6474 | 15639 | 31675196 |
Hypercholesterolaemia | 50.18 | 23.33 | 27 | 6482 | 8003 | 31682832 |
Squamous cell carcinoma of skin | 49.43 | 23.33 | 29 | 6480 | 10145 | 31680690 |
Anti-cyclic citrullinated peptide antibody positive | 48.39 | 23.33 | 16 | 6493 | 1404 | 31689431 |
Keratoacanthoma | 47.72 | 23.33 | 13 | 6496 | 586 | 31690249 |
Phototherapy | 47.06 | 23.33 | 8 | 6501 | 32 | 31690803 |
Joint ankylosis | 44.27 | 23.33 | 14 | 6495 | 1066 | 31689769 |
Bone cyst | 43.27 | 23.33 | 14 | 6495 | 1147 | 31689688 |
Pain in extremity | 40.89 | 23.33 | 80 | 6429 | 116123 | 31574712 |
Treatment failure | 40.83 | 23.33 | 46 | 6463 | 40746 | 31650089 |
Myalgia | 39.92 | 23.33 | 63 | 6446 | 77195 | 31613640 |
Hyperkeratosis | 37.90 | 23.33 | 17 | 6492 | 3403 | 31687432 |
Muscular weakness | 34.67 | 23.33 | 54 | 6455 | 65394 | 31625441 |
Malignant melanoma stage I | 34.35 | 23.33 | 7 | 6502 | 86 | 31690749 |
Basal cell carcinoma | 34.23 | 23.33 | 29 | 6480 | 18150 | 31672685 |
Induration | 33.95 | 23.33 | 11 | 6498 | 905 | 31689930 |
Osteolysis | 33.85 | 23.33 | 14 | 6495 | 2301 | 31688534 |
Botryomycosis | 33.57 | 23.33 | 6 | 6503 | 34 | 31690801 |
Hidradenitis | 32.54 | 23.33 | 11 | 6498 | 1033 | 31689802 |
Neuroendocrine tumour of the lung metastatic | 32.46 | 23.33 | 7 | 6502 | 115 | 31690720 |
Macule | 31.79 | 23.33 | 11 | 6498 | 1108 | 31689727 |
Emotional distress | 31.43 | 23.33 | 25 | 6484 | 14331 | 31676504 |
Skin exfoliation | 31.13 | 23.33 | 31 | 6478 | 23843 | 31666992 |
Red blood cell sedimentation rate abnormal | 30.26 | 23.33 | 14 | 6495 | 3008 | 31687827 |
Hand deformity | 30.15 | 23.33 | 14 | 6495 | 3033 | 31687802 |
Retinal disorder | 29.94 | 23.33 | 10 | 6499 | 905 | 31689930 |
Decreased immune responsiveness | 28.68 | 23.33 | 11 | 6498 | 1484 | 31689351 |
Insomnia | 27.12 | 23.33 | 60 | 6449 | 94776 | 31596059 |
Acute kidney injury | 26.81 | 23.33 | 12 | 6497 | 279702 | 31411133 |
Toxicity to various agents | 26.80 | 23.33 | 3 | 6506 | 181484 | 31509351 |
Alanine aminotransferase abnormal | 26.65 | 23.33 | 14 | 6495 | 3953 | 31686882 |
Myasthenia gravis | 26.40 | 23.33 | 14 | 6495 | 4029 | 31686806 |
Bone erosion | 25.71 | 23.33 | 13 | 6496 | 3390 | 31687445 |
Erythema | 25.43 | 23.33 | 53 | 6456 | 80352 | 31610483 |
Gastrointestinal infection | 24.15 | 23.33 | 14 | 6495 | 4786 | 31686049 |
Gastrointestinal tube insertion | 23.80 | 23.33 | 9 | 6500 | 1168 | 31689667 |
Diabetes mellitus | 23.76 | 23.33 | 36 | 6473 | 42520 | 31648315 |
Hypereosinophilic syndrome | 23.49 | 23.33 | 6 | 6503 | 210 | 31690625 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 1435.48 | 19.03 | 593 | 14143 | 97840 | 70815868 |
Skin haemorrhage | 231.31 | 19.03 | 85 | 14651 | 10095 | 70903613 |
Drug ineffective | 201.48 | 19.03 | 533 | 14203 | 939219 | 69974489 |
Skin exfoliation | 177.62 | 19.03 | 116 | 14620 | 48510 | 70865198 |
Skin plaque | 165.88 | 19.03 | 66 | 14670 | 9717 | 70903991 |
Vein rupture | 154.50 | 19.03 | 41 | 14695 | 1652 | 70912056 |
Neurologic neglect syndrome | 145.10 | 19.03 | 42 | 14694 | 2339 | 70911369 |
Carotid artery thrombosis | 142.32 | 19.03 | 42 | 14694 | 2504 | 70911204 |
Cutaneous T-cell lymphoma | 124.90 | 19.03 | 38 | 14698 | 2515 | 70911193 |
Psoriatic arthropathy | 120.36 | 19.03 | 103 | 14633 | 64668 | 70849040 |
Erythrodermic psoriasis | 117.43 | 19.03 | 33 | 14703 | 1651 | 70912057 |
Respiratory tract congestion | 111.46 | 19.03 | 60 | 14676 | 17593 | 70896115 |
Personality disorder | 110.23 | 19.03 | 42 | 14694 | 5506 | 70908202 |
Squamous cell carcinoma | 107.48 | 19.03 | 55 | 14681 | 14549 | 70899159 |
Pityriasis rubra pilaris | 106.05 | 19.03 | 19 | 14717 | 108 | 70913600 |
Sneezing | 102.53 | 19.03 | 56 | 14680 | 16895 | 70896813 |
Sinus congestion | 101.24 | 19.03 | 56 | 14680 | 17317 | 70896391 |
Sinus disorder | 99.35 | 19.03 | 57 | 14679 | 18902 | 70894806 |
Injection site haemorrhage | 90.96 | 19.03 | 60 | 14676 | 25467 | 70888241 |
Affect lability | 88.83 | 19.03 | 43 | 14693 | 10103 | 70903605 |
Venous injury | 88.52 | 19.03 | 22 | 14714 | 680 | 70913028 |
Dermatitis exfoliative generalised | 87.36 | 19.03 | 37 | 14699 | 6377 | 70907331 |
Sensory loss | 86.92 | 19.03 | 44 | 14692 | 11375 | 70902333 |
Pruritus | 84.62 | 19.03 | 207 | 14529 | 345353 | 70568355 |
Inappropriate schedule of product administration | 83.17 | 19.03 | 107 | 14629 | 107448 | 70806260 |
Motor dysfunction | 78.55 | 19.03 | 43 | 14693 | 13027 | 70900681 |
Adjustment disorder | 77.91 | 19.03 | 28 | 14708 | 3116 | 70910592 |
Hemiplegia | 73.40 | 19.03 | 42 | 14694 | 13853 | 70899855 |
Rhinorrhoea | 72.83 | 19.03 | 79 | 14657 | 66292 | 70847416 |
Keratoacanthoma | 72.19 | 19.03 | 20 | 14716 | 949 | 70912759 |
Skin lesion | 71.08 | 19.03 | 61 | 14675 | 38399 | 70875309 |
Pain of skin | 67.91 | 19.03 | 36 | 14700 | 10230 | 70903478 |
Coordination abnormal | 67.75 | 19.03 | 42 | 14694 | 16024 | 70897684 |
Injection site papule | 65.51 | 19.03 | 18 | 14718 | 828 | 70912880 |
Pustular psoriasis | 63.91 | 19.03 | 27 | 14709 | 4623 | 70909085 |
Toxicity to various agents | 63.64 | 19.03 | 4 | 14732 | 382168 | 70531540 |
Muscle spasticity | 62.30 | 19.03 | 43 | 14693 | 19646 | 70894062 |
Eating disorder | 62.19 | 19.03 | 42 | 14694 | 18523 | 70895185 |
Influenza | 54.16 | 19.03 | 90 | 14646 | 113610 | 70800098 |
Erythema | 53.54 | 19.03 | 124 | 14612 | 199439 | 70714269 |
Cystitis | 53.46 | 19.03 | 57 | 14679 | 46884 | 70866824 |
Therapeutic product effect incomplete | 53.27 | 19.03 | 92 | 14644 | 119790 | 70793918 |
Rhesus antigen positive | 48.87 | 19.03 | 10 | 14726 | 124 | 70913584 |
Muscular weakness | 48.67 | 19.03 | 96 | 14640 | 138240 | 70775468 |
Hemiparesis | 44.58 | 19.03 | 43 | 14693 | 31426 | 70882282 |
Hyperkeratosis | 44.49 | 19.03 | 24 | 14712 | 7060 | 70906648 |
Skin erosion | 44.38 | 19.03 | 20 | 14716 | 3996 | 70909712 |
Aphasia | 43.16 | 19.03 | 49 | 14687 | 43200 | 70870508 |
Squamous cell carcinoma of skin | 43.15 | 19.03 | 29 | 14707 | 12683 | 70901025 |
Phototherapy | 41.10 | 19.03 | 7 | 14729 | 28 | 70913680 |
Rash pustular | 41.07 | 19.03 | 26 | 14710 | 10282 | 70903426 |
Induration | 40.95 | 19.03 | 15 | 14721 | 1761 | 70911947 |
Oral lichen planus | 40.46 | 19.03 | 12 | 14724 | 727 | 70912981 |
Granuloma annulare | 39.04 | 19.03 | 11 | 14725 | 555 | 70913153 |
Onychalgia | 39.00 | 19.03 | 12 | 14724 | 824 | 70912884 |
Joint ankylosis | 38.97 | 19.03 | 14 | 14722 | 1555 | 70912153 |
Influenza like illness | 37.00 | 19.03 | 56 | 14680 | 65275 | 70848433 |
Guttate psoriasis | 36.89 | 19.03 | 10 | 14726 | 437 | 70913271 |
Acute kidney injury | 36.81 | 19.03 | 27 | 14709 | 474597 | 70439111 |
Skin fissures | 36.56 | 19.03 | 25 | 14711 | 11245 | 70902463 |
Infected dermal cyst | 35.07 | 19.03 | 12 | 14724 | 1155 | 70912553 |
Rebound psoriasis | 34.13 | 19.03 | 8 | 14728 | 192 | 70913516 |
Injection site swelling | 33.42 | 19.03 | 43 | 14693 | 43114 | 70870594 |
Arthritis | 33.25 | 19.03 | 67 | 14669 | 97913 | 70815795 |
Dry skin | 33.18 | 19.03 | 49 | 14687 | 55882 | 70857826 |
Neuroendocrine tumour of the lung metastatic | 32.32 | 19.03 | 7 | 14729 | 116 | 70913592 |
Arterial occlusive disease | 32.03 | 19.03 | 20 | 14716 | 7722 | 70905986 |
Hypercholesterolaemia | 31.97 | 19.03 | 28 | 14708 | 18089 | 70895619 |
Malignant melanoma stage I | 31.47 | 19.03 | 7 | 14729 | 132 | 70913576 |
Myalgia | 31.25 | 19.03 | 91 | 14645 | 167801 | 70745907 |
Skin injury | 31.13 | 19.03 | 14 | 14722 | 2784 | 70910924 |
Nasopharyngitis | 30.94 | 19.03 | 109 | 14627 | 222097 | 70691611 |
Bone cyst | 30.77 | 19.03 | 14 | 14722 | 2860 | 70910848 |
Gangrene | 30.73 | 19.03 | 20 | 14716 | 8289 | 70905419 |
Pain in extremity | 30.57 | 19.03 | 142 | 14594 | 327940 | 70585768 |
Death | 30.20 | 19.03 | 37 | 14699 | 510024 | 70403684 |
Hypotension | 30.07 | 19.03 | 24 | 14712 | 404357 | 70509351 |
Dyslipidaemia | 29.94 | 19.03 | 21 | 14715 | 9839 | 70903869 |
Immunoglobulins decreased | 29.07 | 19.03 | 11 | 14725 | 1413 | 70912295 |
Macule | 28.88 | 19.03 | 13 | 14723 | 2590 | 70911118 |
Weaning failure | 28.73 | 19.03 | 9 | 14727 | 656 | 70913052 |
Wrong technique in device usage process | 28.65 | 19.03 | 14 | 14722 | 3354 | 70910354 |
Neutropenia | 28.46 | 19.03 | 9 | 14727 | 257147 | 70656561 |
Skin atrophy | 28.27 | 19.03 | 16 | 14720 | 5163 | 70908545 |
Osteolysis | 28.07 | 19.03 | 14 | 14722 | 3505 | 70910203 |
Skin disorder | 27.94 | 19.03 | 33 | 14703 | 30324 | 70883384 |
Blood immunoglobulin M decreased | 27.84 | 19.03 | 10 | 14726 | 1110 | 70912598 |
Type IIb hyperlipidaemia | 27.67 | 19.03 | 5 | 14731 | 30 | 70913678 |
Dysphagia | 26.87 | 19.03 | 67 | 14669 | 112767 | 70800941 |
Anaemia | 26.34 | 19.03 | 27 | 14709 | 403396 | 70510312 |
Lichen planus | 26.04 | 19.03 | 12 | 14724 | 2523 | 70911185 |
Palmoplantar pustulosis | 25.98 | 19.03 | 8 | 14728 | 551 | 70913157 |
Blood albumin increased | 25.46 | 19.03 | 10 | 14726 | 1420 | 70912288 |
Somnolence | 24.85 | 19.03 | 7 | 14729 | 215599 | 70698109 |
Botryomycosis | 24.66 | 19.03 | 5 | 14731 | 59 | 70913649 |
Cataract | 23.78 | 19.03 | 42 | 14694 | 55603 | 70858105 |
Tanning | 23.37 | 19.03 | 5 | 14731 | 78 | 70913630 |
Cutaneous symptom | 23.35 | 19.03 | 7 | 14729 | 440 | 70913268 |
Inflammatory bowel disease | 23.34 | 19.03 | 14 | 14722 | 5032 | 70908676 |
Burning sensation | 22.71 | 19.03 | 40 | 14696 | 52830 | 70860878 |
Blood pressure increased | 22.49 | 19.03 | 88 | 14648 | 188429 | 70725279 |
Psoriasis area severity index increased | 21.83 | 19.03 | 5 | 14731 | 108 | 70913600 |
Infusion related reaction | 21.70 | 19.03 | 7 | 14729 | 197527 | 70716181 |
Tongue ulceration | 21.66 | 19.03 | 12 | 14724 | 3719 | 70909989 |
Dysarthria | 21.59 | 19.03 | 43 | 14693 | 62270 | 70851438 |
Dehydration | 21.56 | 19.03 | 10 | 14726 | 226132 | 70687576 |
Dizziness | 21.34 | 19.03 | 40 | 14696 | 464101 | 70449607 |
Hepatic cirrhosis | 21.29 | 19.03 | 29 | 14707 | 30702 | 70883006 |
Hidradenitis | 21.13 | 19.03 | 11 | 14725 | 3011 | 70910697 |
Oesophageal stenosis | 20.86 | 19.03 | 12 | 14724 | 3992 | 70909716 |
Hyponatraemia | 20.82 | 19.03 | 4 | 14732 | 160083 | 70753625 |
Tonsil cancer | 20.81 | 19.03 | 8 | 14728 | 1073 | 70912635 |
Thrombocytopenia | 20.68 | 19.03 | 12 | 14724 | 239098 | 70674610 |
Ichthyosis | 20.66 | 19.03 | 5 | 14731 | 138 | 70913570 |
Hepatic fibrosis | 20.56 | 19.03 | 14 | 14722 | 6253 | 70907455 |
Cerebrovascular accident | 20.49 | 19.03 | 71 | 14665 | 143399 | 70770309 |
Platelet count decreased | 20.14 | 19.03 | 6 | 14730 | 178216 | 70735492 |
Seizure | 20.10 | 19.03 | 6 | 14730 | 177956 | 70735752 |
Constipation | 20.01 | 19.03 | 14 | 14722 | 252424 | 70661284 |
Tremor | 20 | 19.03 | 4 | 14732 | 155620 | 70758088 |
Diffuse idiopathic skeletal hyperostosis | 19.67 | 19.03 | 4 | 14732 | 48 | 70913660 |
Sunburn | 19.41 | 19.03 | 11 | 14725 | 3560 | 70910148 |
Basal cell carcinoma | 19.23 | 19.03 | 29 | 14707 | 33669 | 70880039 |
Decreased appetite | 19.20 | 19.03 | 21 | 14715 | 304759 | 70608949 |
None
Source | Code | Description |
---|---|---|
ATC | D05BB02 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis |
FDA CS | M0018962 | Retinoids |
FDA EPC | N0000175607 | Retinoid |
CHEBI has role | CHEBI:50176 | keratolytic drugs |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D007641 | Keratolytic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Severe Recalcitrant Psoriasis | indication | ||
Lichen planus | off-label use | 4776004 | DOID:9201 |
Keratosis follicularis | off-label use | 48611009 | DOID:2734 |
Lamellar ichthyosis | off-label use | 205550003 | |
Ichthyosiform erythroderma | off-label use | 268282005 | |
Primary cutaneous T-cell lymphoma | off-label use | 400122007 | |
Alcoholism | contraindication | 7200002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Depressive disorder | contraindication | 35489007 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Night blindness | contraindication | 65194006 | DOID:8499 |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Premature epiphyseal closure | contraindication | 89493005 | |
Liver function tests abnormal | contraindication | 166603001 | |
Hypoalphalipoproteinemia | contraindication | 190785000 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Hypertrophy of bone | contraindication | 203514008 | DOID:205 |
Drug-induced hepatitis | contraindication | 235876009 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Cardiovascular event risk | contraindication | 395112001 | |
Visual impairment | contraindication | 397540003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Psychiatric Disturbance | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.17 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
Bile salt export pump | Transporter | IC50 | 4.74 | CHEMBL | |||||
Bile salt export pump | Transporter | IC50 | 4.71 | CHEMBL |
ID | Source |
---|---|
4021061 | VUID |
N0000148524 | NUI |
D02754 | KEGG_DRUG |
16818 | RXNORM |
C0050559 | UMLSCUI |
CHEBI:50173 | CHEBI |
CHEMBL1131 | ChEMBL_ID |
DB00459 | DRUGBANK_ID |
D017255 | MESH_DESCRIPTOR_UI |
5284513 | PUBCHEM_CID |
7598 | IUPHAR_LIGAND_ID |
5530 | INN_ID |
LCH760E9T7 | UNII |
004121 | NDDF |
108914001 | SNOMEDCT_US |
386938006 | SNOMEDCT_US |
4021061 | VANDF |
69427-46-9 | SECONDARY_CAS_RN |
11379 | MMSL |
117161 | MMSL |
4128 | MMSL |
d03836 | MMSL |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1135 | CAPSULE | 10 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1135 | CAPSULE | 10 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1135 | CAPSULE | 10 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1136 | CAPSULE | 25 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1136 | CAPSULE | 25 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1136 | CAPSULE | 25 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1138 | CAPSULE | 17.50 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1138 | CAPSULE | 17.50 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1138 | CAPSULE | 17.50 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1750 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1751 | CAPSULE | 17.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1752 | CAPSULE | 22.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1753 | CAPSULE | 25 mg | ORAL | ANDA | 17 sections |
SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0090 | CAPSULE | 10 mg | ORAL | NDA | 27 sections |
SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0091 | CAPSULE | 25 mg | ORAL | NDA | 27 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7020 | CAPSULE | 10 mg | ORAL | ANDA | 28 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7020 | CAPSULE | 10 mg | ORAL | ANDA | 28 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7023 | CAPSULE | 25 mg | ORAL | ANDA | 28 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7023 | CAPSULE | 25 mg | ORAL | ANDA | 28 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-086 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-087 | CAPSULE | 17.50 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-088 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-080 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-081 | CAPSULE | 17.50 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-083 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-894 | CAPSULE | 10 mg | ORAL | NDA authorized generic | 16 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-896 | CAPSULE | 25 mg | ORAL | NDA authorized generic | 16 sections |